Search Results

You are looking at 1 - 10 of 97 items for :

  • "mitomycin" x
Clear All
Full access

Yixing Jiang, Heath Mackley, Hua Cheng and Jaffer A. Ajani

anal cancer. However, treatment failure is frequent in patients with bulky primary tumors and regional lymphadenopathy. To improve the efficacy of chemoradiation, several approaches have been investigated, including changing mitomycin-based chemotherapy

Full access

Shree Vishnu Siddarth, Ginil Kumar Pooleri and Georgie Mathew

Introduction: The recurrence following a transurethral resection (TUR) of non-muscle invasive bladder cancer (NMIBC) remains relatively high. A single immediate postoperative instillation of mitomycin C (MMC) reduces the rate of recurrence in the

Full access

Stephen A. Brassell and Ashish M. Kamat

Meyer R . A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin . J Urol 1996 ; 156

Full access

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer and Robert A. Wolff

pancreatic cancer. Abbreviations: MMC, mitomycin C; RT, radiation therapy; SBRT, stereotactic body radiation therapy. a Based on performance status (see NCCN Guidelines for Pancreatic Adenocarcinoma 14 ). b Cui Y, Brosnan JA, Blackford AL, et al

Full access

Joseph M. Pepek, Christopher G. Willett and Brian G. Czito

since the report by Nigro et al. 1 was published in 1974. These initial results documented that 5-fluorouracil (5-FU) and mitomycin-C (MMC) combined with pelvic RT yielded improved local control rates with sphincter preservation. Randomized trials have

Full access

Keli Turner, Sheelu Varghese and H. Richard Alexander

intraperitoneal chemotherapy (HIPEC), usually with mitomycin C or cisplatin, has been largely established as the best initial therapeutic intervention in selected patients with DMPM. The intent of operation with CRS and HIPEC is to remove all gross disease and

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass

mitomycin or porfiromycin, suggesting that it might be possible to cure anal carcinoma without surgery and permanent colostomy. Subsequent nonrandomized studies using similar regimens and varied doses of chemoRT provided support for this conclusion. 25 , 26

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Jordan D. Berlin, J. Michael Berry, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric Rohren, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small Jr., Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

)–based concurrent chemoRT, including either mitomycin or porfiromycin, suggesting that anal carcinoma may be possible to cure without surgery and permanent colostomy. Subsequent nonrandomized studies using similar regimens and varied doses of chemotherapy and

Full access

Michael R. Abern, Richmond A. Owusu, Mark R. Anderson, Edward N. Rampersaud and Brant A. Inman

did not show a benefit on recurrence, whereas the other 5 drugs did ( Figure 4 ). Because epirubicin and mitomycin were administered to most of the patients in the trials, a separate random-effects model was performed on this subset. The RR for

Full access

Peyman Haghighat and Tanios Bekaii-Saab

chemotherapy plus best supportive care with best supportive care in advanced gastric cancer . Ann Oncol 1997 ; 8 : 163 – 168 . 5. MacDonald JS Schein PS Woolley PV . 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for